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Abstract
Biallelic mutations in G‐Protein coupled receptor kinase 1 (GRK1) cause Oguchi
disease, a rare subtype of congenital stationary night blindness (CSNB). The purpose
of this study was to identify disease causing GRK1 variants and use in‐depth
bioinformatic analyses to evaluate how their impact on protein structure could lead
to pathogenicity. Patients’ genomic DNA was sequenced by whole genome, whole
exome or focused exome sequencing. Disease associated variants, published and
novel, were compared to nondisease associated missense variants. The impact of
GRK1 missense variants at the protein level were then predicted using a series of
computational tools. We identified twelve previously unpublished cases with bial-
lelic disease associated GRK1 variants, including eight novel variants, and reviewed
all GRK1 disease associated variants. Further structure‐based scoring revealed a
hotspot for missense variants in the kinase domain. In addition, to aid future clinical
interpretation, we identified the bioinformatics tools best able to differentiate
disease associated from nondisease associated variants. We identified GRK1 var-
iants in Oguchi disease patients and investigated how disease‐causing variants may
impede protein function in‐silico.
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1 | INTRODUCTION
The first member of the G protein‐coupled receptor kinase (GRK)
family was discovered when enzymatic activity was observed in rod
membranes that phosphorylated rhodopsin in a light‐dependent
manner (Kuhn & Dreyer, 1972). The enzyme, now known as GRK1
(MIM# 180381), was found to be essential for quenching and re-
cycling light‐activated rhodopsin. To be recycled, light‐activated
rhodopsin is phosphorylated multiple times by GRK1, followed by
binding of Arrestin‐1 to activated‐phosphorylated rhodopsin to block
further transducin activation by steric exclusion (Krupnick et al.,
1997; Wilden et al., 1986). Failure of this process results in a build‐up
of activated rhodopsin, which continues to activate the photo-
transduction cascade, shutting off circulating current in the rod
photoreceptors, rendering them unable to respond electrically to
light. Importantly, a build‐up of activated rhodopsin appears to be
well tolerated by photoreceptors, with no obvious cell death or
structural consequences in the retina, meaning any future therapies
leading to the deactivation of rhodopsin could restore visual acuity.
Activated cone opsin is likely to be more reliant on GRK7 than GRK1
phosphorylation, as although both enzymes are expressed in cones,
loss of GRK1 function has minimal impact on human photopic vision.
GRK1 is a serine/threonine protein kinase with a central cata-
lytic AGC protein kinase (PK) domain that sits within a regulator of G
protein signaling homology (RH) domain (Figures 1 and 3). The PK
domain binds ATP and the polypeptide substrate which is subse-
quently phosphorylated (Arencibia et al., 2013). The RH domain is
thought to have a key role in receptor binding, with loss of this
domain preventing binding and phosphorylation of rhodopsin (He
et al., 2017). While the N‐terminus encodes a short alpha‐helical
domain, the C‐terminus encodes a lipid‐binding region, which is
crucial for prenylation‐dependent docking of GRK1 into the outer
segment membranes of rod photoreceptors (Komolov &
Benovic, 2018).
Oguchi disease (MIM# 613411), a rare form of congenital sta-
tionary night blindness (CSNB), results from biallelic variants in ei-
ther SAG (encoding Arrestin‐1) or GRK1. SAG‐mediated disease is
most prevalent in Japanese patients, whilst pathogenic variants in
GRK1 are more common in South East Asians. Typically, Oguchi
disease is characterized clinically by the Mizuo–Nakamura
phenomenon—the presence of a golden‐yellow colouration to the
retina that disappears in the dark‐adapted state and reappears
shortly after light exposure (Miyake et al., 1996). Electro-
physiologically there is normal cone function, delayed rod dark
adaptation and marked rod desensitization to a bright flash. Most
reported cases have this distinctive phenotype and no significant
variation in disease expression has been reported, with the exception
of a few rare cases (Hayashi et al., 2007; Nishiguchi et al., 2019).
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Distinguishing between Oguchi disease and other forms of CSNB is
important as they may have different prognoses—some patients with
Oguchi disease report very slowly progressive visual dysfunction,
whereas those with classical CSNB do not. Minimally progressive
retinal degeneration has been observed in SAG‐associated Oguchi
disease, and for one patient, this resulted in their disease being re‐
classified as retinitis pigmentosa 26 years after being diagnosed with
a stationary rod dysfunction syndrome (Oguchi disease; Nishiguchi
et al., 2019). As most of our knowledge of Oguchi disease stems from
our understanding of loss of SAG function further research is re-
quired to better understand GRK1‐related Oguchi disease.
To date, thirteen pathogenic variants in GRK1 have been im-
plicated in Oguchi disease, eight of which are predicted to be null
variants (Azam et al., 2009; Cideciyan et al., 1998; Godara et al., 2012;
Hayashi et al., 2007; Jespersgaard et al., 2019; Li et al., 2017; Mucciolo
et al., 2018; Oishi et al., 2007; Skorczyk‐Werner et al., 2015;
Teke et al., 2016; Yamamoto et al., 1997; Q. Zhang et al., 2005).
The molecular mechanisms by which these contribute to disease are
poorly understood. Here, we present eight further disease associated,
likely pathogenic variants in GRK1 and review new and known var-
iants causing Oguchi disease. Using in‐silico techniques we compare
likely pathogenic disease‐associated variants with nonpathogenic
GRK1missense variants to identify features that could be contributing
to the phenotype. Together this will help define disease mechanisms
and assist in predicting likelihood of pathogenicity for variants
identified in GRK1.
2 | METHODS
2.1 | Editorial policies and ethical considerations
Ethical approval for this study was obtained from the Yorkshire
and The Humber – Leeds East Research Ethics Committee (REC
F IGURE 1 Distribution of disease associated variants within GRK1. All variants shown are annotated according to human genome
GRCh37/hg19, using GRK1 gene and protein accession numbers NM_002929 and NP_002920, respectively. Loss of function variants are
shown above the gene/protein and missense variants are given below. (a) Genomic organization of GRK1 showing the location of all novel and
published Oguchi disease causing variants. (b) Domain structure of GRK1 showing the location of all GRK1 variants. The start and end
amino‐acid positions of each domain are based on Lodowski et al. (2006). NT, N‐terminus; RH, regulator of G‐protein signaling homology
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reference: 17/YH/0032). The study adhered to the tenets of the
Declaration of Helsinki. Blood samples were taken with informed
consent from each participant, or with parental informed consent on
behalf of children.
2.2 | Clinical assessment
Study participants were ascertained from St James’ University
Hospital, Leeds, England; Manchester Centre for Genomic
F IGURE 2 Bioinformatic prediction scores of disease associated and nondisease associated GRK1 variants. Comparison of predicted
pathogenicity scores for all novel or published disease associated missense GRK1 variants, with likely nonpathogenic missense variants
identified in gnomAD. The whiskers in the box plots show the minimum and maximum values. Statistical significance was calculated using
Welch's t‐test in GraphPad prism 8.0.2. ns = p ≥ .05, * = p < .05, ** = p < .01, *** = p < .001, **** = p < .0001. (a) Wildtype (WT) residue depth (Å)
from site‐directed mutator (SDM), (b) WT occluded surface packing (OSP) from SDM, (c) thermostability score SDM, (d) disease propensity
scores as predicted in VarSite, (e) SIFT scores, (f) PolyPhen‐2 scores, (g) CADD (v1.3) scores, (h) Rhapsody scores and (i) ConSurf predicted roles
(1 = structural/functional role predicted, 0 = no role predicted). DAVs, disease associated variants; NDAVs, nondisease associated variants
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F IGURE 3 – Location of disease associated and nondisease associated variants in a homology model of GRK1. Homology model of
human GRK1 based upon bovine GRK1 structure (PDB: 4PNI). Wildtype residues of disease associated variants are labeled in red
(Leu157, Gly199, Leu308, Arg332, Glu362, Ala377, Val380, Pro391, and Arg438) and nondisease associated variants in blue (Leu54,
Thr97, Ile241, Glu464, and Ser536). The protein kinase domain is colored in purple, RH domain in orange, activation loop in green, ATP
binding residues are represented as yellow sticks and polypeptide substrate binding residues as cyan sticks. (a) A visualization of variant
location in the overall structure. Variants are highlighted as beads. The smaller representations to the right, with the ATP and
polypeptide binding surface displayed demonstrate how intramolecular residue changes may deform the binding site surface. (b) A focus
on residue location and local interactions, displaying only features within 15 Å of the residue of interest. Variant residue atoms are
represented as spheres
POULTER ET AL. | 5
Medicine, Manchester, England; Moorfields Eye Hospital, Lon-
don, England; Department of Ophthalmology, Ghent University
Hospital, Ghent, Belgium; The Jikei University School of Medi-
cine, Tokyo, Japan; Mie University Graduate School of Medicine,
Mie, Japan; and National Institute of Sensory Organs, National
Hospital Organization Tokyo Medical Centre, Tokyo Japan; in-
dividuals were recruited following clinical examination by an
experienced ophthalmologist, with the exception of Families 10
and 11 who were ascertained by local doctors in Pakistan.
2.3 | Sequencing
Exome and clinical exome sequencing was performed on 3 µg of
genomic DNA using the Agilent SureSelectXT Human All Exon (V6) and
Focussed Exome respectively (Agilent Technologies), according to the
manufacturer's instructions. Captured libraries were pooled and se-
quenced on an Illumina HiSeq3000 sequencer (Illumina). The resulting
fastq files were aligned to the Human genome assembly GRCh37 using
Burrows‐Wheeler Aligner and reads processed using samtools, Picard,
and the Genome Analysis Toolkit. Variants within the captured regions
were called and annotated using variant effect predictor (NCBI) and
further filtered for those within genes known to cause retinal disease.
This analysis pipeline is described in more detail elsewhere (Panagiotou
et al., 2017). Copy number variation analysis was performed using
ExomeDepth, comparing patient BAM files with BAM files from un-
related individuals in the same sequencing run. All novel variants were
confirmed by Sanger sequencing using standard methods.
The affected individual and unaffected parents of Family 1
underwent Genome sequencing as part of the 100,000 Genome
Project, as previously detailed by Taylor et al. (2017).
2.4 | Identifying nonpathogenic variants
To identify protein‐level characteristics influencing a disease phenotype
we compared the nine disease associated missense variants with a
group of five assumed nondisease associated missense variants. For the
nonpathogenic variants, we identified all homozygous GRK1 missense
variants in gnomAD and only included those with a MAF>0.00035, the
level above which variants are calculated to be too common to cause
Oguchi disease (Whiffin et al., 2017). The five missense variants in
gnomAD with frequencies above this level, p.Leu54Phe, p.Thr97Met,
p,Ile241Thr, p.Glu464Gln, and p.Ser536Leu, also all occur at least once
as homozygotes in gnomAD. These are therefore assumed to be non-
disease associated polymorphisms (further details in Table S1).
2.5 | Structural analysis
A homology model of human wild‐type GRK1 based on the bovine
structure (PDB: 4PNI) was produced using SwissModel
(Waterhouse et al., 2018). The locations of the RH and PK
domains, ATP binding site, polypeptide substrate binding site and
activation loop were identified using InterPro (Mitchell et al.,
2019). The structure was visualized, and regions of interest la-
beled using PyMOL (Schrodinger, 2015). Residue depth and
connectivity within the structure was determined using Site‐
Directed Mutator (SDM; Pandurangan et al., 2017). To further
explain variant impact, changes in residue physical character-
istics; molecular weight, isoelectric point, and hydrophobicity
(Laskowski et al., 2020) were reviewed.
2.6 | Scoring missense variants
A number of bioinformatics tools were reviewed to identify
which approach best classified the variants. Scoring methods
included: SDM (Pandurangan et al., 2017), VarSite (Laskowski
et al., 2020), SIFT v6.2.1 (Sim et al., 2012), Polyphen‐2 v2.2.2r394
(Adzhubei et al., 2010), CADD v1.3 (Kircher et al., 2014), Rhap-
sody (Ponzoni et al., 2019), and ConSurf (Ashkenazy et al., 2016).
All statistical analyses were performed in GraphPad Prism 8.0.2
(for macOS, GraphPad Software, www.graphpad.com) using
Welch's t‐test.
3 | RESULTS
3.1 | Identification of novel GRK1 variants
associated with Oguchi disease
Screening of inherited retinal disease patients by an international
consortium of retinal genetics laboratories identified 12 cases
with Oguchi disease harboring nine different disease associated
variants in GRK1, of which eight are previously unreported
(Table 1). The majority of cases in this study were identified in
families of South Asian descent, except for Family 2 who are East
Asian (Japanese) and Family 5 who are Eastern European (Polish).
All variants were confirmed and segregated in available family
members (summarized in Figure S1). Each patient had a history of
non/minimally progressive night blindness, and retinal examina-
tion revealed the Mizuo–Nakamura phenomenon, consistent with
a clinical diagnosis of Oguchi disease.
A literature search revealed a further thirteen published
Oguchi disease causing GRK1 variants from 12 studies
(Azam et al., 2009; Cideciyan et al., 1998; Godara et al., 2012;
Hayashi et al., 2007; Jespersgaard et al., 2019; Li et al., 2017;
Mucciolo et al., 2018; Oishi et al., 2007; Skorczyk‐Werner et al.,
2015; Teke et al., 2016; Yamamoto et al., 1997; Q. Zhang et al.,
2005). The nomenclature for these variants was updated based
on the current HGVS nomenclature guidelines and the GRCh37
version of the Human Genome, and together with the new
variants reported here, these have been included in a Leiden
Open Variation Database (LOVD) of GRK1 variants (http://dna2.
leeds.ac.uk/GRK1_LOVD/genes/GRK1).
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3.2 | Disease associated variant distribution and
domain structure
The 21 Oguchi disease associated variants (DAVs) identified to date
include missense (n = 10), frameshift (n = 6), and nonsense (n = 4)
variants (Table 1) as well as a large deletion encompassing exon 5
(Figure 1a). Each variant has been identified in only a single family
with the exception of p.Val380Asp (two families), p.Glu48ProfsTer82
(two families), the deletion of exon 5 (p.(Phe358GlyfsTer18); three
families), and the C‐terminal frameshift variant p.(Asp537ValfsTer6;
six families), with the latter variant having the highest allele fre-
quency in gnomAD (89/172,958). Of the 89 p.Asp537ValfsTer7 al-
leles in gnomAD, 42 are in European (non‐Finnish) and 35 in South
Asian populations, which is consistent with this mutation being
identified in cases from Eastern Europe and South Asia in this study.
Sixteen of the variants lie within the protein kinase domain,
three within the RH domain and one at each of the N‐ and C‐termini
(Figure 1b). While the frameshift and nonsense variants are present
throughout the protein, all except one of the missense variants (n = 8
out of 9) are present within the protein kinase domain (Figure 2a),
and five cluster within a 30 amino‐acid region between Glu362 and
Pro391 (Figure 2a). These are likely to impair phosphorylation of
light‐activated rhodopsin.
Three variants located after this cluster introduce frameshifts in
the final exon, giving rise to transcripts which would not be expected
to undergo nonsense‐mediated decay (Thermann et al., 1998). The
extreme C‐terminus of GRK1, which these three variants would
disrupt, is prenylated to facilitate anchoring of GRK1 in the mem-
branes of the rod photoreceptor outer segments (Pitcher et al.,
1998), which maximizes the likelihood of interaction with activated
rhodopsin. Lack of this domain is therefore likely to reduce the level
of anchored GRK1, which will in turn reduce the quantity of rho-
dopsin being bound and phosphorylated.
3.3 | Disease associated missense variants affect
key regions in GRK1 active site
To further understand the mechanism by which the missense var-
iants affected GRK1 function, we performed structure‐based scoring
on the SDM server using our homology model (Figure 2a–c). Al-
though SDM's primary function is predicting thermal stability, the
most interesting results came from the scoring of wildtype (WT)
residue depth and occluded surface packing (OSP), with both scores
showing a significant difference between DAVs and likely non‐
pathogenic, nondisease associated variants (NDAVs) (p = .0021 and
p = .0390 respectively). This demonstrated that DAVs were located
deeper within the three‐dimensional (3D) structure of GRK1 than
NDAVs (residue depth = 3.5–11.8 and 3–6.2, respectively; Figure 2a,
Table S2) and were more connected/densely packed (OSP = 0.3–0.61
and 0.04–0.48, respectively; Figure 2b, Table S2). Exceptions to
these rules were seen in DAV p.Gly199Arg, which is located at the
surface of the protein (residue depth = 3.5 Å and OSP = 0.3), and
NDAV p.Ile241Thr, which is located deeper in GRK1 (residue
depth = 6.2 and OSP = 0.48). Gly199 is positioned within the con-
served glycine rich loop of the PK domain and is part of the ATP
binding site (Figure 3). Mutation to a bulky positively charged argi-
nine (Table S2) is likely to disrupt both the shape and charge of the
ATP binding pocket (Figure 3). Although Ile241 is buried in the
binding pocket of the PK domain (Figure 3), there is little change in
size and charge (Table S2) which could explain why this variant is
nonpathogenic.
Further investigation of mutation location in the protein
structure demonstrated DAVs were located proximal to key sites
for protein function, including the substrate and ATP binding
domains, while NDAVs were not (Figure 3a). DAVs were pre-
dicted to be likely to disrupt the shape and charge of the active
site either directly as in the case of p.Gly199Arg and
p.Arg332Trp, or allosterically through introduction of proline
kinks into alpha helices (e.g., p.Leu308Pro and p.Ala377Pro), in-
tramolecular charged groups (classically exposed; e.g., p.Va-
l380Asp and p.Pro391His), and bulky side groups within densely
packed regions (e.g., p.Val380Phe) close to key residues
(Figure 3b and Table S2). In the case of p.Arg438Cys and
p.Glu362Lys, the equivalent arginine and glutamic acid residues
are conserved and form a salt bridge in the bovine protein
(Figure S2). It is therefore likely that substitution of Glu362 and
Arg438 changes the charge of these residues in the human pro-
tein and is disrupting this salt bridge interaction (Figure S2).
Meanwhile NDAVs were often subtler changes, and not local to
key residues (Figure 3b and Table S2). We hypothesize DAVs
within the protein kinase domain are inhibiting protein function
through disruption of the shape and dynamics of this key region,
while NDAVs prove less disruptive to shape as they are not in-
ternal and/or have subtler changes in residue characteristics.
This is supported by Consurf's prediction that most of the DAVs
occur at loci important for protein structure or function
(Figure 2i and Table S2).
Only one DAV, p.Leu157Pro, lies outside of the kinase domain,
instead being present within the RH domain of GRK1, the domain
primarily responsible for rhodopsin binding (He et al., 2017). The
introduction of a proline residue within an α‐helix is likely to disrupt
the secondary structure and introduce a characteristic “kink” due to
its rigidity and constrained phi angle. This could potentially impact on
the ability of Rhodopsin to correctly bind GRK1 in order for phos-
phorylation to occur.
To determine which bioinformatic tools were most successful in
differentiating between disease associated and nondisease asso-
ciated variants, we scored missense variants using: VarSite, SDM,
PolyPhen‐2, SIFT, CADD, Rhapsody, and Consurf. Predictions were
compared between DAV and NDAV sets, with significance assessed
by Welch's t‐test (Figure 2, Tables 1, and S2). VarSite disease pro-
pensity, WT OSP, WT residue depth, PolyPhen‐2, CADD, Rhapsody,
and Consurf, were able to distinguish between DAVs and NDAVs
with statistical significance. Consurf's structure/function prediction
and Rhapsody, which both take the variant's location in the protein
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3D structure into consideration, were able to differentiate between
disease associated and nondisease associated most successfully
(p < .0001; Figure 2h,i and Table S2).
Rhapsody has the additional feature of being able to predict the
impact of substituting any residue in a protein with all of the 19
other amino acids (in silico site‐directed mutagenesis), making it
extremely valuable diagnostically, as it has the potential to inform
future work by identifying residue changes which are likely to be
poorly tolerated. We performed protein‐wide site‐directed muta-
genesis and reviewed the top scoring variants (Rhapsody score
≥ 0.896). This analysis revealed that the top scoring variants were
present at just 22 loci across the protein, thus identifying a number
of key residues with the potential to cause Oguchi disease, if mu-
tated. Of the 22 amino acid residues that Rhapsody predicts could
harbor the most damaging variants, 20 are located in the protein
kinase domain (Figure 4).
4 | DISCUSSION
Using a combined genetics and structural biology approach we have
identified individuals with Oguchi disease due to biallelic GRK1
variants and inferred the likely functional consequences of these and
other published variants. We identified eight new disease associated
variants, taking the total number of GRK1 variants associated with
Oguchi disease to 21. While eleven result in premature termination
codons, 10 result in single amino acid substitutions.
It is likely that transcripts encoding nonsense and frameshift
variants, except those in the last exon, will be subject to nonsense
mediated decay (NMD; Thermann et al., 1998). This has not been
confirmed in patient cells, but even if a truncated GRK1 was ex-
pressed, previous studies have shown that GRK1 protein lacking the
residues encoded by exon 5 had significantly reduced function, re-
sulting in protein that was not able to phosphorylate Rhodopsin
(Cideciyan et al., 1998). This implies that lack of functional GRK1
protein is one mechanism by which Oguchi disease can arise.
Eight of the 10 observed missense variants, and 20 of the 22 top
Rhapsody scorers lie within the protein kinase domain, which is
critical for GRK1 function. The kinase domain is the largest within
GRK1, and variants in this region are likely to have a negative impact
on phosphorylation of light‐activated rhodopsin. Indeed, a previous
study has shown the p.Val380Asp variant has no kinase activity for
Rhodopsin compared with wild‐type GRK1 (Khani et al., 1998). Five
missense variants appear to be clustered within a 30 amino‐acid
region between Glu362 and Pro391, which may imply that amino‐
acid substitutions in this region are more likely to disrupt protein
function than those located elsewhere. These variants were pre-
dicted to affect the structure of GRK1 and therefore kinase activity.
As the structural analysis relies on a homology model of human
GRK1, it is not always feasible to quantify atomic level changes
F IGURE 4 – Rhapsody top scoring substitutions mapped onto the homology model of GRK1. Homology model of human GRK1 based upon
bovine GRK1 structure (PDB: 4PNI). Wildtype residues of top‐scoring ((≥0.896) Rhapsody variants are highlighted as beads, and labeled,
colored and numbered based on residue number. The colors and labels within the bar chart of top‐scoring Rhapsody variants mimic this format.
Locations with more than four variants in the top 93 scores include: G68, L253, L308, Y315, L318, Y383, L430, and G440
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(e.g., the formation of novel H‐bond or salt bridge interactions, or the
disruption of interactions within non‐conserved residues). However,
it is possible to draw general conclusions about the surrounding
residue location and impact on secondary and tertiary structure.
Therefore, loss of kinase activity through disruption of its shape and
dynamics is a second mechanism by which Oguchi disease can occur.
Three variants have been identified in the last exon of GRK1, all
of which result in frameshift transcripts that potentially escape
nonsense mediated decay, leading to a GRK1 protein with a dis-
rupted C‐terminus. This region plays a crucial role in embedding
GRK1 within the photoreceptor outer segment membrane; GRK1
localizes directly to the outer segment membranes due to a short
prenylation sequence within the C‐terminus that interacts with the
prenyl‐binding protein, delta (PrBP/δ), which facilitates attachment
to the membranes (Huang et al., 2011; Roosing et al., 2014). Deletion
of PrBP/δ has also been shown to result in impaired trafficking of
prenylated‐GRK1 to photoreceptor outer segments, highlighting the
importance of this interaction in correct localization of GRK1 (H.
Zhang et al., 2007). This cellular localization is essential for GRK1
function as it brings active rhodopsin into contact with docked GRK1
protein through a two‐dimensional search rather than 3D diffusion,
which is essential for ultrarapid signal termination (Sato et al., 2015).
Lack of this sequence is likely to cause failure of prenylation, leading
to abolished binding of PrBP/δ, incorrect localization of GRK1 and a
reduction in Rhodopsin phosphorylation, a third mechanism by which
disease can arise. This is supported by studies showing a marked
reduction in Rhodopsin phosphorylation in cells transfected with the
p.Asp537ValfsTer7 variant (Khani et al., 1998).
One missense variant, p.Leu157Pro, was identified in the
N‐terminal RH domain, which of the two RH domains present in
GRK1, contains most of the Rhodopsin binding capacity (~70%).
While complete loss of the N‐terminal RH domain has been shown to
cause a significant reduction in Rhodopsin binding (He et al., 2017),
no studies have yet determined the effect of single amino acid sub-
stitutions on this activity. The importance of Leu157, however, is
highlighted by it being conserved across all known human GRKs,
suggesting it is crucial for the function of the protein. Binding of
Rhodopsin has also been shown to require the protein kinase domain
to be in an active conformation (Homan & Tesmer, 2014), therefore
missense substitutions in the kinase domain may also have an impact
on Rhodopsin binding. Further studies are required to determine the
full extent of missense substitutions on GRK1 function.
Our study therefore highlights three potential molecular me-
chanisms by which GRK1 variants lead to disease, each of which
ultimately reduce or abolish the phosphorylation of light‐activated
rhodopsin. These are (a) lack of GRK1 protein due to frame shift or
nonsense variants in all exons but the last, resulting in NMD; (b)
missense variants leading to inability of GRK1 to phosphorylate
rhodopsin due to a dysfunctional kinase domain or failure to bind
rhodopsin, ATP or Mg2+; or (c) a frameshift in the final exon, which
would be expected to escape nonsense mediated decay and produce
a protein retaining the ability to bind and phosphorylate light‐
activated rhodopsin, but which cannot localize to the outer segment
membranes. We would therefore predict that, while variants in the
first category lead to no protein being produced, those in the second
produce proteins that correctly localize within the outer segments
but have inhibited kinase activity, and those in the third produce a
GRK1 protein likely to maintain kinase activity but which fails to
localize and so rarely comes into contact with activated rhodopsin.
Interestingly, the kinase activity of the p.(Asp537ValfsTer6) variant
was found to be significantly reduced in transfected cos7 cells,
suggesting C‐terminal mutations may affect kinase activity as well as
protein localization. However, this lack of activity may be explained
by difficulties in expressing the mutation containing GRK1 protein
rather than on protein function (Khani et al., 1998).
Our comparison of GRK1 DAVs to NDAVs identified from gno-
mAD facilitated an assessment of pathogenicity scores, which could
inform future variant interpretation. We found that VarSite disease
propensity, Polyphen2, CADD, Rhapsody and Consurf were able to
significantly differentiate between DAVs and NDAVs, as were bio-
physical scores of residue depth and occluded surface packing.
Rhapsody was the best of all the tools at differentiating between
DAVs and NDAVs. Rhapsody incorporates dynamics information
from elastic network models of protein structure, as well as
PolyPhen‐2 and EVMutation (conservation) scores using a machine
learning approach. This broad range of sequence‐, structure‐, and
dynamics‐based information could account for its success since the
impact of a variant can arise from a multitude of different physio‐
chemical effects. Despite producing the best separation (Rhapsody)
and describing features (SDM), structure‐based tools are limited by
the availability of the protein's structure or a homologous structure.
Although homology models are not always accurate for atomic level
information, coarser detail such as whether residues are buried is
likely to be reliable. Similarly, although ConSurf can be used without
a pdb structure it is dependent on homologous proteins having a
structure. In this study we found using ConSurf without a pdb
structure was sufficient to predict pathogenicity based on whether a
residue is likely to be buried or exposed, relating to its location in
homologous proteins with known structures. Ultimately, these scores
can only be used as a guide, and variant pathogenicity should be
confirmed by segregation analysis and functional assays wherever
possible, as rare nonpathogenic variants can also score highly.
Interrogation of gnomAD revealed a further three rare variants
that were homozygous in at least one individual and could not be
excluded as a cause of Oguchi disease based on allele frequency
alone (Table S3 and Figure S3). We therefore calculated the same set
of pathogenic prediction scores to assess the likely pathogenicity of
these variants of unknown significance. The p.Met185Val variant,
although rare in gnomAD, produced scores that were comparable
with the NDAVs for each tool, suggesting it does not contribute to
disease. However, both p.Ala353Ser and p.Ala387Val, produced
scores that were compatible with DAVs, suggesting that the two
individuals in gnomAD that are homozygous for these variants may
have Oguchi disease. gnomAD contains exome and genome sequence
data from over 130,000 unrelated individuals, with only those in-
dividuals affected by a severe pediatric disorder being removed. It is
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therefore possible that individuals with CSNB or Oguchi disease are
present in the gnomAD database which could explain the presence of
two homozygous, likely DAVs.
In summary, we present eight novel variants in GRK1 as a cause
of Oguchi disease and perform an in‐depth analysis of all GRK1
variants to understand their contribution to disease. We describe
three mechanisms likely to account for all GRK1‐related disease,
each of which ultimately result in a failure to phosphorylate light‐
activated rhodopsin. We assessed the ability of different in silico
pathogenicity scores to differentiate DAVs and NDAVs and found
that Rhapsody out‐performed all tools tested for this data set. Fi-
nally, we have created an LOVD database into which all the known
DAVs and several common NDAVs described herein have been en-
tered, to guide future variant interpretation in GRK1‐associated
disease.
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